Trials / Completed
CompletedNCT01936337
Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients
A Multi-center, Double-blinded, Randomized, Placebo-controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of a Topical Application of DLX105 Onto Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Delenex Therapeutics AG · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, the safety, tolerability and efficacy of DLX105 administered topically onto the psoriatic lesion of mild-to-moderate psoriasis patients will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DLX105 Hydrogel | topical administration on psoriatic plaque |
| DRUG | Placebo | topical administration on psoriatic plaque |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-06-01
- Completion
- 2014-07-01
- First posted
- 2013-09-06
- Last updated
- 2014-08-12
Locations
3 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT01936337. Inclusion in this directory is not an endorsement.